KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
11.70
-0.23 (-1.93%)
At close: Jun 24, 2025, 4:00 PM
12.00
+0.30 (2.56%)
Pre-market: Jun 25, 2025, 7:03 AM EDT
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 150 employees as of April 30, 2024. The number of employees increased by 32 or 27.12% compared to the previous year.
Employees
150
Change (1Y)
32
Growth (1Y)
27.12%
Revenue / Employee
n/a
Profits / Employee
-$1,172,447
Market Cap
581.67M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
KALV News
- 9 days ago - KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis - Business Wire
- 11 days ago - US FDA extends review of KalVista's swelling disorder drug due to heavy workload - Reuters
- 11 days ago - KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints - Business Wire
- 20 days ago - KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025 - Business Wire
- 21 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 23 days ago - KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management - Business Wire
- 27 days ago - KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings - Business Wire